Diagnostic problems and postnatal follow-up in congenital toxoplasmosis

Minerva Pediatrica

Volumn 59, Issue 3, 2007, Pages 207-213

  Mazzola, A ^a,c   Casuccio, A ^b   Romano, A ^a   Schimmenti, M G ^a   Titone, L ^b   Di Carlo, P ^b  

^a ARNAS Civico Benfratelli G di Cristina and M Ascoli   (Italy)

^b UNIVERSITY OF PALERMO   (Italy)

^c NONE   (Italy)

Author keywords

Toxoplasmosis diagnosis; Toxoplasmosis, congenital; Toxoplasmosis, drug therapy

Indexed keywords

PYRIMETHAMINE SULFADIAZINE; SPIRAMYCIN; SULFADIAZINE;

ARTICLE; CONGENITAL TOXOPLASMOSIS; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; POSTNATAL CARE; PRENATAL DIAGNOSIS; RISK FACTOR;

ADOLESCENT; ADULT; AMNIOCENTESIS; ANIMALS; ANTIMALARIALS; ANTIPROTOZOAL AGENTS; BIOLOGICAL MARKERS; COCCIDIOSTATS; DISEASE TRANSMISSION, VERTICAL; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; INFANT; POLYMERASE CHAIN REACTION; PREGNANCY; PREGNANCY COMPLICATIONS, PARASITIC; PREGNANCY TRIMESTERS; PROSPECTIVE STUDIES; PYRIMETHAMINE; RETROSPECTIVE STUDIES; SICILY; SULFADIAZINE; TOXOPLASMOSIS, CONGENITAL; TREATMENT OUTCOME;

EID: 34447513072     PISSN: 00264946     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Foulon W, Villena I, Stray-Pedersen B, Decoster A, Lappalainen M, Pinon JM et al. Treatment of toxoplasmosis during pregnancy: a multicenter study of impact on fetal transmission and children's sequelae at 1 year. Am J Obstet Gynaecol 1999;280:410-15.
2. Dunn D, Wallon M, Peyron F, Petersen E, Peckham CS, Gilbert RE. Mother to child transmission of Toxoplasmosis: risk estimates for clinical counselling. Lancet 1999;353:1829-33.
3. Armstrong L, Isaacs D, Evans N. Severe neonatal toxoplasmosis after third trimester maternal infection. Pediatr Infect Dis J 2004;23:968-9.
4. Foulon W, Pinon JM, Stray-Pedersen B, Pollak A, Lapplainen M Decoster A et al. Prenatal diagnosis of congenital toxoplasmosis: a multicenter evaluation of different diagnostic parameters. Am J Obstet Gynecol 1999;181:843-7.
5. Antsaklis A, Daskalakis G, Papantoniou N, Mentis A, Michalas S. Prenatal diagnosis of congenital toxoplasmosis. Prenat Diagn 2002;22:1107-11.
6. Chabbert E, Lachaud L, Crobu L, Bastien P. Comparison of two widely used PCR primer systems for detection of toxoplasma in amniotic fluid, blood and tissues. J Clin Microbiol 2004;42:1719-22.
7. McAuley J, Boyer KM, Patel D, Mets M, Swisher C, Roizen N et al. Early and longitudinal evaluations of treated infants and children and untreated historical patients with congenital toxoplasmosis: the Chicago Collaborative Treatment Trial. Clin Infect Dis 1994;18:38-72.
8. Lebech M, Joynson DH, Seitz HM, Thulliez P, Gilbert RE, Dutton GN et al. Classification system and case definitions of Toxoplasma gondii infection in immunocompetent pregnant women and their congenitally infected offspring. European Research Network on Congenital Toxoplasmosis. Eur J Clin Microbiol Infect Dis 1996;15:799-805.
9. National Committee for Clinical Laboratory Standards. Specifications for immunological testing for infectious diseases. Approved guideline. 1994. NCCLS document I/LA18-A. National Committee for Clinical Laboratory Standards, Wayne, Pa.
10. Hohlfeld P, Daffos F, Costa JM, Thulliez P, Forestier F, Vidaud M. Prenatal diagnosis of congenital toxoplasmosis with a polymerase-chain-reaction test on amniotic fluid. N Engl J Med 1994;331:695-9.
11. Gussetti N. Present in Program of Consensesus Nazionale sulla Toxoplasmosi in gravidanza. Padova, 1998; Abstract book p 55.
12. Preis K, Ciach K, Swiatkowska-Freund M. The risk of complications of diagnostic and therapeutic cordocentesis. Ginekol Pol 2004;75:765-9.
13. Nassar AH, Martin D, Gonzales-Quintero VH, Gomez-Martin O, Salman F, Gutierrez A et al. Genetic amniocentesis complication: is the incidence overrated? Gynecol Obstet Invest 2004;58:100-4.
14. Gay-Andrieu F, Marty P, Pialat Jean, Sournies G, De Laforte TD, Peyron F. Fetal toxoplasmosis and negative amniocentesis: necessity of an ultrasound follow-up. Prenatal Diagnosis 2003;23:558-60.
15. th edition. Philadelphia: Saunders; 2001.p.205-346.
16. Vergani P, Ghiaini A, Ceruti P, Strobelt N, Spelta A, Zapparoli B et al. Congenital toxoplasmosis: efficacy of maternal treatment with spyramicin alone. Am J Reprod Immunol 1998;39:335-40.
17. Kravets JD, Ferdman DG. Toxoplasmosis in pregnancy. Am J Med 2005;118:212-6.
18. Lopez A, Dietz VJ, Wilson M, Navin TR, Jones JL. Preventing congenital toxoplasmosis. MMWR 2000;49:57-75.
19. Guerina NG, Hsu HW, Meissner HC, Maguire JH, Lynfield R, Stechenberg B et al. Neonatal serologic screening and early treatment for congenital Toxoplasma gondii infection. New England Regional Toxoplasma Working Group. N Engl J Med 1994;330:1858-63.
20. Romand S, ChossonM, Franck J, Wallon M, Kieffer F, Kaiser K et al. Usefulness of quantitative polymerase chain reaction in amniotic fluid as early prognostic marker of fetal infection with Toxoplasma gondii. Am J Obstet Gynecol 2004;190:797-802.